MERTK receptor tyrosine kinase is a therapeutic target in melanoma

Cancer statistics, 2012

(2012) Rebecca Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

A Landscape of Driver Mutations in Melanoma

(2012) Eran Hodis et al.   CELL

The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity

(2012) Jordi Barretina et al.   NATURE

Mer or Axl receptor tyrosine kinase inhibition promotes apoptosis, blocks growth and enhances chemosensitivity of human non-small cell lung cancer

(2012) R M A Linger et al.   ONCOGENE

A prognostic signature of defective p53-dependent G1 checkpoint function in melanoma cell lines

(2012) Craig Carson et al.   Pigment Cell & Melanoma Research

Reviewing the somatic genetics of melanoma: from current to future analytical approaches

(2012) Ken Dutton-Regester et al.   Pigment Cell & Melanoma Research

Prolonged Exposure to a Mer Ligand in Leukemia: Gas6 Favors Expression of a Partial Mer Glycoform and Reveals a Novel Role for Mer in the Nucleus

(2012) Justine Migdall-Wilson et al.   PLoS One

Discovery of Small Molecule Mer Kinase Inhibitors for the Treatment of Pediatric Acute Lymphoblastic Leukemia

(2012) Jing Liu et al.   ACS Medicinal Chemistry Letters

Melanoma whole-exome sequencing identifies V600E B-RAF amplification-mediated acquired B-RAF inhibitor resistance

(2012) Hubing Shi et al.   Nature Communications

Human Cutaneous Melanomas Lacking MITF and Melanocyte Differentiation Antigens Express a Functional Axl Receptor Kinase

(2011) Marialuisa Sensi et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Phosphoproteomic Screen Identifies Potential Therapeutic Targets in Melanoma

(2011) K. Tworkoski et al.   MOLECULAR CANCER RESEARCH

RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)

(2011) Poulikos I. Poulikakos et al.   NATURE

Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation

(2011) Paul B. Chapman et al.   NEW ENGLAND JOURNAL OF MEDICINE

Mer receptor tyrosine kinase inhibition impedes glioblastoma multiforme migration and alters cellular morphology

(2011) A E J Rogers et al.   ONCOGENE

Reversing Melanoma Cross-Resistance to BRAF and MEK Inhibitors by Co-Targeting the AKT/mTOR Pathway

(2011) Mohammad Atefi et al.   PLoS One

Melanoma cells show a heterogeneous range of sensitivity to ionizing radiation and are radiosensitized by inhibition of B-RAF with PLX-4032

(2011) Maria J. Sambade et al.   RADIOTHERAPY AND ONCOLOGY

Frequencies of BRAF and NRAS mutations are different in histological types and sites of origin of cutaneous melanoma: a meta-analysis

(2010) J.-H. Lee et al.   BRITISH JOURNAL OF DERMATOLOGY

Melanoma biomarker expression in melanocytic tumor progression: a tissue microarray study

(2010) Rosalynn M. Nazarian et al.   JOURNAL OF CUTANEOUS PATHOLOGY

Inhibition of Mer and Axl Receptor Tyrosine Kinases in Astrocytoma Cells Leads to Increased Apoptosis and Improved Chemosensitivity

(2010) A. K. Keating et al.   MOLECULAR CANCER THERAPEUTICS

COT drives resistance to RAF inhibition through MAP kinase pathway reactivation

(2010) Cory M. Johannessen et al.   NATURE

Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation

(2010) Ramin Nazarian et al.   NATURE

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

(2010) F. Stephen Hodi et al.   NEW ENGLAND JOURNAL OF MEDICINE

NCBI GEO: archive for functional genomics data sets--10 years on

(2010) T. Barrett et al.   NUCLEIC ACIDS RESEARCH

Differential Expression of Axl and Gas6 in Renal Cell Carcinoma Reflecting Tumor Advancement and Survival

(2009) A. Gustafsson et al.   CLINICAL CANCER RESEARCH

A genomic screen identifies TYRO3 as a MITF regulator in melanoma

(2009) S. Zhu et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

The gene expression profiles of primary and metastatic melanoma yields a transition point of tumor progression and metastasis

(2008) Adam I Riker et al.   BMC Medical Genomics